Tarsus Pharmaceuticals Inc. (TARS) News
Filter TARS News Items
TARS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TARS News Highlights
- TARS's 30 day story count now stands at 5.
- Over the past 11 days, the trend for TARS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- NOV and EYE are the most mentioned tickers in articles about TARS.
Latest TARS News From Around the Web
Below are the latest news stories about TARSUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TARS as an investment opportunity.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2023 Earnings Call TranscriptTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2023 Earnings Call Transcript November 10, 2023 Operator: Good afternoon and welcome to the Tarsus Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to David Nakasone, Head of Investor Relations to […] |
Analysts Are Betting On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) With A Big Upgrade This WeekTarsus Pharmaceuticals, Inc. ( NASDAQ:TARS ) shareholders will have a reason to smile today, with the analysts making... |
Tarsus Reports Third Quarter 2023 Financial Results and Recent Business AchievementsLaunched XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis Achieved $1.7 million in net product sales with more than 1,700 dispensed bottles Strengthened balance sheet with an approximately $100 million public equity offering Management to host conference call today, November 9, 2023, at 1:30 p.m. P.T. / 4:30 p.m. E.T. IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and a |
Recent uptick might appease Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) institutional owners after losing 11% over the past yearKey Insights Institutions' substantial holdings in Tarsus Pharmaceuticals implies that they have significant influence... |
Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, November 9, 2023 to report its third quarter 2023 financial results and provide a corporate update. A live webcast and additional information about the presentati |
Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex BlepharitisIRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, MD, PhD, Chief Executive Officer and Chairman, will ring the closing bell at the Nasdaq Stock Market on Wednesday, September 6, 2023. The event marks the launch of XDEMVY™, which is now available at pharmacies nationwi |
Tarsus to Present at Upcoming Investor ConferencesIRVINE, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Strategy Officer, will participate in the following conferences, both located in New York City, NY: H.C. Wainwright 25th Annual Glo |
15 Most Shorted Stocks That Are Loved By AnalystsIn this piece, we will take a look at the 15 most shorted stocks that are loved by analysts. If you want to skip our introduction to short selling, then jump ahead to 5 Most Shorted Stocks That Are Loved By Analysts. Short selling is a tricky game. Rapid share price appreciations can stretch a […] |
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex BlepharitisDemodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available via prescription from an eye care provider Sales force deployed, calling on ophthalmologists and optometrists nationwide IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology |
Insider Spends US$160k Buying More Shares In Tarsus PharmaceuticalsInvestors who take an interest in Tarsus Pharmaceuticals, Inc. ( NASDAQ:TARS ) should definitely note that the Chief... |